ADAR1 reports 8.8% stake in Boundless Bio
Boundless Bio, Inc. has disclosed that private investment funds managed by ADAR1 Capital Management, LLC beneficially own 1,968,216 shares of its common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Boundless Bio, Inc. has disclosed that private investment funds managed by ADAR1 Capital Management, LLC beneficially own 1,968,216 shares of its common stock. This represents 8.8% of Boundless Bio’s common stock, based on 22,475,000 shares outstanding as of June 30, 2026.
The shares are reported as being subject to shared voting and dispositive power by ADAR1 Capital Management and Daniel Schneeberger, who is the sole manager of ADAR1 Capital Management and may be deemed to indirectly beneficially own the same 1,968,216 shares.
Key Figures
Key Terms
beneficially owned financial
Schedule 13G regulatory
control person regulatory
investment adviser financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much of Boundless Bio, Inc. (BOLD) does ADAR1 Capital Management beneficially own?
Who are the reporting persons in this Schedule 13G for Boundless Bio (BOLD)?
In what capacity is Daniel Schneeberger reporting ownership in Boundless Bio (BOLD)?
Where are the principal offices of Boundless Bio (BOLD) and the reporting persons located?
AI-generated analysis. How Rhea-AI works. Not financial advice.